Sugi Predict

Sugi Predict / Compounds / SCHEMBL2534433

SCHEMBL2534433

SCHEMBL2534433

CCOC(=O)c1n[nH]c(N)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4D Q08499 1/20 0.47
▸ ALDH1A1 P00352 7/20 0.46
▸ HPGD P15428 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ CYP1A2 P05177 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ LMNA P02545 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAOA P21397 1/20 0.41
▸ ADORA2A P29274 1/20 0.40
▸ ADORA1 P30542 1/20 0.40
▸ MAPK10 P53779 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2528048 0.83 LMNA (0.46) PDE4DALDH1A1KDM4ECYP1A2MAPT
SCHEMBL15498679 0.81 PDE4D (0.50) PDE4DALDH1A1HPGDMEN1KMT2A
SCHEMBL10602243 0.80 PDE4D (0.49) PDE4DALDH1A1HPGDMEN1KMT2A
SCHEMBL2578827 0.79 PDE4D (0.45) PDE4DALDH1A1HPGDMEN1KMT2A
SCHEMBL28661103 0.79 PDE4D (0.47) PDE4DALDH1A1HPGDMEN1KMT2A
SCHEMBL17619378 0.79 PDE4D (0.51) PDE4DALDH1A1HPGDMEN1KMT2A
SCHEMBL2887664 0.79 PDE4D (0.47) PDE4DALDH1A1HPGDMEN1KMT2A
SCHEMBL11431099 0.79 PDE4D (0.47) PDE4DALDH1A1HPGDMEN1KMT2A
SCHEMBL352579 0.78 CYP1A2 (0.54) PDE4DALDH1A1HPGDMEN1KMT2A
SCHEMBL1207051 0.77 SMYD3 (0.32) ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119875248-A Wear-resistant flexible high polymer material and preparation method thereof 小水牛科技(宁波)有限公司 2025-04-25 — — CN claimed
CN-115141190-B 1,2, 4-triazolyl-1, 3, 4-oxadiazole energetic compound and preparation method thereof 南京理工大学 2024-01-12 — — CN claimed
WO-2023103853-A1 CLEANING FLUID AND USE THEREOF 安集微电子科技（上海）股份有限公司 2023-06-15 — — WO claimed
CN-116254159-A Cleaning fluid and application thereof 安集微电子科技（上海）股份有限公司 2023-06-13 — — CN claimed
CN-115141190-A 1,2, 4-triazol-1, 3, 4-oxadiazole energetic compound and preparation method thereof 南京理工大学 2022-10-04 — — CN claimed
CN-119875248-A Wear-resistant flexible high polymer material and preparation method thereof 小水牛科技(宁波)有限公司 2025-04-25 — — CN disclosed
CN-115141190-B 1,2, 4-triazolyl-1, 3, 4-oxadiazole energetic compound and preparation method thereof 南京理工大学 2024-01-12 — — CN disclosed
WO-2023103853-A1 CLEANING FLUID AND USE THEREOF 安集微电子科技（上海）股份有限公司 2023-06-15 — — WO disclosed
CN-116254159-A Cleaning fluid and application thereof 安集微电子科技（上海）股份有限公司 2023-06-13 — — CN disclosed
CN-110062758-B Bicyclic dihydropyrimidine-carboxamide derivatives as RHO-kinase inhibitors 奇斯药制品公司 2023-01-17 — — CN disclosed
CN-115141190-A 1,2, 4-triazol-1, 3, 4-oxadiazole energetic compound and preparation method thereof 南京理工大学 2022-10-04 — — CN disclosed
WO-2020239074-A1 BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND APPLICATION THEREOF 南京明德新药研发有限公司 2020-12-03 — — WO disclosed
US-20150158878-A1 BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS 4SC DISCOVERY GMBH (DE) 2015-06-11 — — US disclosed
EP-2867237-A1 BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS 4SC Discovery GmbH (DE) 2015-05-06 — — EP disclosed
WO-2014202638-A1 2,3-DIHYDROBENZOFURAN-5-YL COMPOUNDS AS DYRK KINASE INHIBITORS 4SC DISCOVERY GMBH (DE) 2014-12-24 — — WO disclosed
WO-2014001464-A1 BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS 4SC DISCOVERY GMBH (DE) 2014-01-03 — — WO disclosed
US-8330039-B2 Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound E I DU PONT DE NEMOURS AND COMPANY (US) 2012-12-11 — — US disclosed
EP-2380208-A1 SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND E. I. du Pont de Nemours and Company (US) 2011-10-26 — — EP disclosed
WO-2010085664-A1 SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-07-29 — — WO disclosed
US-20100180947-A1 SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158878-A1 BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS CHUK, KYNU, BLK PDE4D 3249/4885ALDH1A1 2657/4885HPGD 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.